Literature DB >> 20497311

Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting.

W N Southern1, M-L Drainoni, B D Smith, C L Christiansen, D McKee, A L Gifford, C M Weinbaum, D Thompson, E Koppelman, S Maher, A H Litwin.   

Abstract

Approximately 3.2 million persons are chronically infected with the hepatitis C virus (HCV) in the U.S.; most are not aware of their infection. Our objectives were to examine HCV testing practices to determine which patient characteristics are associated with HCV testing and positivity, and to estimate the prevalence of HCV infection in a high-risk urban population. The study subjects were all patients included in the baseline phase of the Hepatitis C Assessment and Testing Project (HepCAT), a serial cross-sectional study of HCV screening strategies. We examined all patients with a clinic visit to Montefiore Medical Center from 1/1/08 to 2/29/08. Demographic information, laboratory data and ICD-9 diagnostic codes from 3/1/97-2/29/08 were extracted from the electronic medical record. Risk factors for HCV were defined based on birth date, ICD-9 codes and laboratory data. The prevalence of HCV infection was estimated assuming that untested subjects would test positive at the same rate as tested subjects, based on risk-factors. Of 9579 subjects examined, 3803 (39.7%) had been tested for HCV and 438 (11.5%) were positive. The overall prevalence of HCV infection was estimated to be 7.7%. Risk factors associated with being tested and anti-HCV positivity included: born in the high-prevalence birth-cohort (1945-64), substance abuse, HIV infection, alcohol abuse, diagnosis of cirrhosis, end-stage renal disease, and alanine transaminase elevation. In a high-risk urban population, a significant proportion of patients were tested for HCV and the prevalence of HCV infection was high. Physicians appear to use a risk-based screening strategy to identify HCV infection.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 20497311      PMCID: PMC2990787          DOI: 10.1111/j.1365-2893.2010.01327.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  35 in total

Review 1.  Evaluation of abnormal liver-enzyme results in asymptomatic patients.

Authors:  D S Pratt; M M Kaplan
Journal:  N Engl J Med       Date:  2000-04-27       Impact factor: 91.245

Review 2.  EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement.

Authors: 
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

3.  Evaluation of the effectiveness of targeted lookback for HCV infection in the United States-interim results.

Authors:  D H Culver; M J Alter; R J Mullan; H S Margolis
Journal:  Transfusion       Date:  2000-10       Impact factor: 3.157

4.  Cost-effectiveness of screening patients for hepatitis C.

Authors:  F D Gordon
Journal:  Am J Med       Date:  1999-12-27       Impact factor: 4.965

5.  Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults.

Authors:  M E Singer; Z M Younossi
Journal:  Am J Med       Date:  2001-12-01       Impact factor: 4.965

6.  Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness.

Authors:  S D Rosenberg; L A Goodman; F C Osher; M S Swartz; S M Essock; M I Butterfield; N T Constantine; G L Wolford; M P Salyers
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

7.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

8.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

9.  Updated definitions of healthy ranges for serum alanine aminotransferase levels.

Authors:  Daniele Prati; Emanuela Taioli; Alberto Zanella; Emanuela Della Torre; Sonia Butelli; Emanuela Del Vecchio; Luciana Vianello; Francesco Zanuso; Fulvio Mozzi; Silvano Milani; Dario Conte; Massimo Colombo; Girolamo Sirchia
Journal:  Ann Intern Med       Date:  2002-07-02       Impact factor: 25.391

10.  Guideline-concordant hepatitis C virus testing and notification among patients with and without mental disorders.

Authors:  Amy M Kilbourne; John F McCarthy; Seth Himelhoch; Deborah Welsh; Peter Hauser; Frederic C Blow
Journal:  Gen Hosp Psychiatry       Date:  2008-08-09       Impact factor: 3.238

View more
  33 in total

1.  Survey of US Correctional Institutions for Routine HCV Testing.

Authors:  Curt G Beckwith; Ann E Kurth; Lauri Bazerman; Liza Solomon; Emily Patry; Josiah D Rich; Irene Kuo
Journal:  Am J Public Health       Date:  2015-01       Impact factor: 9.308

2.  Developing a multidisciplinary model of comparative effectiveness research within a clinical and translational science award.

Authors:  Paul R Marantz; A Hal Strelnick; Brian Currie; Rohit Bhalla; Arthur E Blank; Paul Meissner; Peter A Selwyn; Elizabeth A Walker; Daphne T Hsu; Harry Shamoon
Journal:  Acad Med       Date:  2011-06       Impact factor: 6.893

3.  Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004-2010.

Authors:  Reena Mahajan; Stephen J Liu; R Monina Klevens; Scott D Holmberg
Journal:  Am J Public Health       Date:  2013-06-13       Impact factor: 9.308

4.  Results of Hepatitis C Birth-Cohort Testing and Linkage to Care in Selected U.S. Sites, 2012-2014.

Authors:  Rajiv C Patel; Claudia Vellozzi; Bryce D Smith
Journal:  Public Health Rep       Date:  2016 May-Jun       Impact factor: 2.792

5.  No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort or Risk-Based Screening.

Authors:  Brianna L Norton; William N Southern; Meredith Steinman; Bryce D Smith; Joseph Deluca; Zachary Rosner; Alain H Litwin
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-19       Impact factor: 11.382

Review 6.  Rapid diagnostic HCV antibody assays.

Authors:  Bryce D Smith; Amy Jewett; Jan Drobeniuc; Saleem Kamili
Journal:  Antivir Ther       Date:  2012-12-07

7.  Previous exposure to HCV among persons born during 1945-1965: prevalence and predictors, United States, 1999-2008.

Authors:  Bryce D Smith; Geoff A Beckett; Anthony Yartel; Deborah Holtzman; Nita Patel; John W Ward
Journal:  Am J Public Health       Date:  2014-01-16       Impact factor: 9.308

8.  Surgeon general's perspectives.

Authors:  Boris D Lushniak
Journal:  Public Health Rep       Date:  2014-05       Impact factor: 2.792

9.  Comparison of hepatitis C virus testing strategies: birth cohort versus elevated alanine aminotransferase levels.

Authors:  Bryce D Smith; Anthony K Yartel
Journal:  Am J Prev Med       Date:  2014-09       Impact factor: 5.043

10.  Education and counseling in the methadone treatment setting improves knowledge of viral hepatitis.

Authors:  Sandra E Larios; Carmen L Masson; Michael S Shopshire; Jennifer Hettema; Ashly E Jordan; Courtney McKnight; Christopher Young; Mandana Khalili; Randy M Seewald; Albert Min; Nicholas Hengl; James L Sorensen; Don C Des Jarlais; David C Perlman
Journal:  J Subst Abuse Treat       Date:  2013-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.